Dr. Uğur Özberk

Doctor and researcher Ankara Bilkent Şehir Hastanesi Ankara
Carcinoma, Renal CellKidney Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Carcinoma, Renal Cell 2 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Kidney Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • InstitutionAnkara Bilkent Şehir Hastanesisaglik.gov.trFrom source
  • Area of workCarcinoma, Renal CellExtracted from 2 publications · Model version —From source
  • Publications15 publicationsOpenAlex, ORCID, Europe PMCFrom source
  • ORCID0009-0005-9030-022XORCIDFrom source
  • Last synchronised7 November 2026 00:02https://ankarasehir.saglik.gov.tr/TR-331078/tibbi-onkoloji-klinigi-doktorlarimiz.html#ugur-ozberksaglik.gov.tr

Scientific work

Publications on Carcinoma, Renal Cell

15 publications

  1. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15041657 PMID 41753346 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  2. Clinicopathological Features of Intrahepatic Cholangiocarcinoma with Assessment of IDH1 Mutation: A Two-Center Retrospective Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15135290 PMID 42452749 Open-access full textSource: ORCID

  3. Prognostic Value of the Lung Immune Prognostic Index in Metastatic Renal Cell Carcinoma Treated With Second-Line Immunotherapy

    International journal of urology : official journal of the Japanese Urological Association, 2026

    DOI 10.1111/iju.70619 PMID 42655932 Open-access full textSource: Europe PMC

  4. Prediction of postoperative recurrence in non–small cell lung cancer using machine learning approaches.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e20020 Source: OpenAlex

  5. Adjuvant Docetaxel–Cyclophosphamide Versus Anthracycline–Taxane Chemotherapy in Stage I–III HR-Positive/HER2-Negative Breast Cancer: A Real-World Propensity Score Overlap-Weighted Cohort Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15218568 Open-access full textSource: OpenAlex

  6. Clinical and microbiological characteristics of abscesses in patients with malignancy and factors associated with 90-day mortality

    Frontiers in Cellular and Infection Microbiology, 2026

    DOI 10.3389/fcimb.2026.1969735 Open-access full textSource: OpenAlex

  7. Machine learning-based prediction of two-year overall survival in metastatic endometrial cancer: a SEER population-based study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-72830-2 Open-access full textSource: ORCID

  8. Machine learning–based prediction of recurrence after curative resection in non–small cell lung cancer

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-47862-3 PMID 41957214 Open-access full textSource: OpenAlex

  9. Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16667-y PMID 42693417 Open-access full textSource: OpenAlex

  10. Timing of Second-Line Nivolumab and Survival in Metastatic Renal Cell Carcinoma

    Clinical Genitourinary Cancer, 2026

    DOI 10.1016/j.clgc.2026.102653 PMID 42700745 Source: OpenAlex

View all 15 publications